Literature DB >> 27415155

Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.

Yadan Wang1, Xiaofei Wu1, Jun Deng1, Hao Yu2, Ren Xu2, Zhiyi Zhu2, Shichun Tu2, Yu Hu1.   

Abstract

The 8p11 myeloproliferative syndrome (EMS), also known as 8p11 myeloproliferative neoplasm (8p11 MPN), is a collection of rare hematologic malignancies that are associated with fusion genes involving the tyrosine kinase receptor gene FGFR1 in chromosome 8p11. The entity is an aggressive disease with a high rate of transformation to acute myeloid leukemia (AML) and pathologically characterized by its associated eosinophilia. In this study, we reported a distinctive EMS case featuring an in-frame ZMYM2-FGFR1 fusion gene identified by next-generation sequencing technology (NGS). This patient exhibited not only typical EMS signs including elevated white blood cells in peripheral blood and hypercellular bone marrow with marked leukocytosis, but also exceptional characteristics including erythrocytosis in blood and bone marrow basophilia. Moreover, we detected 2 novel genomic mutations in 2 known leukemogenic genes, IKZF1 and ASXL1. Whether these 2 mutations play a part in EMS pathogenesis or contribute to its specific presentations clinically remain to be determined. In summary, we present a unique EMS case involving a ZMYM2-FGFR1 fusion with distinctive hematologic characteristics.

Entities:  

Keywords:  8p11 myeloproliferative syndrome; ASXL1; IKZF1; ZMYM2-FGFR1; eosinophilia; gene rearrangement; leukocytosis; next-generation sequencing; whole-genome sequencing

Mesh:

Substances:

Year:  2016        PMID: 27415155      PMCID: PMC5004680          DOI: 10.1080/15384047.2016.1210727

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  21 in total

1.  Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.

Authors:  E Lierman; S Smits; J Cools; B Dewaele; M Debiec-Rychter; P Vandenberghe
Journal:  Leukemia       Date:  2012-01-17       Impact factor: 11.528

2.  Unique eosinophil granules in a case of T-cell lymphoma.

Authors:  R Manthorpe; J Egeberg; M Hesselvik; A Videbaek
Journal:  Scand J Haematol       Date:  1977-08

3.  Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.

Authors:  Marta Pratcorona; Saman Abbas; Mathijs A Sanders; Jasper E Koenders; François G Kavelaars; Claudia A J Erpelinck-Verschueren; Annelieke Zeilemakers; Bob Löwenberg; Peter J M Valk
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

4.  Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.

Authors:  Andrew Chase; Catherine Bryant; Joannah Score; Nicholas C P Cross
Journal:  Haematologica       Date:  2012-08-08       Impact factor: 9.941

5.  ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.

Authors:  S Schnittger; C Eder; S Jeromin; T Alpermann; A Fasan; V Grossmann; A Kohlmann; T Illig; N Klopp; H-E Wichmann; K-A Kreuzer; C Schmid; P Staib; R Peceny; N Schmitz; W Kern; C Haferlach; T Haferlach
Journal:  Leukemia       Date:  2012-09-11       Impact factor: 11.528

Review 6.  8p11 myeloproliferative syndrome: a review.

Authors:  Courtney C Jackson; L Jeffrey Medeiros; Roberto N Miranda
Journal:  Hum Pathol       Date:  2010-04       Impact factor: 3.466

7.  ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain.

Authors:  S Xiao; J G McCarthy; J C Aster; J A Fletcher
Journal:  Blood       Date:  2000-07-15       Impact factor: 22.113

8.  Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases.

Authors:  José L Vizmanos; Roberto Hernández; María J Vidal; María J Larráyoz; María D Odero; Julián Marín; María T Ardanaz; María J Calasanz; Nicholas C P Cross
Journal:  Hematol J       Date:  2004

9.  A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment.

Authors:  Arjan Buijs; Merel van Wijnen; Dorine van den Blink; Mariëlle van Gijn; Saskia K Klein
Journal:  Cancer Genet       Date:  2013-04

10.  A novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocation.

Authors:  Y Nakamura; Y Ito; N Wakimoto; E Kakegawa; Y Uchida; M Bessho
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

View more
  2 in total

1.  Detection of novel fusion-transcripts by RNA-Seq in T-cell lymphoblastic lymphoma.

Authors:  Pilar López-Nieva; Pablo Fernández-Navarro; Osvaldo Graña-Castro; Eduardo Andrés-León; Javier Santos; María Villa-Morales; María Ángeles Cobos-Fernández; Laura González-Sánchez; Marcos Malumbres; María Salazar-Roa; José Fernández-Piqueras
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

2.  A proximity biotinylation-based approach to identify protein-E3 ligase interactions induced by PROTACs and molecular glues.

Authors:  Satoshi Yamanaka; Yuto Horiuchi; Saya Matsuoka; Kohki Kido; Kohei Nishino; Mayaka Maeno; Norio Shibata; Hidetaka Kosako; Tatsuya Sawasaki
Journal:  Nat Commun       Date:  2022-01-10       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.